Novo Nordisk initiates trial with obesity-treating tablet
On Wednesday afternoon, Novo Nordisk announced that the molecule semaglutide will soon be tested in tablet form in a phase IIIa trial to treat obesity.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk plans to initiate a new phase IIIa trial program against obesity with the firm's molecule semaglutide, according to a press release on Wednesday afternoon.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
